Who can take part?
Patients with breast cancer which is hormone receptor positive and HER2-negative that has progressed, or spread shortly after completing endocrine therapy.
What is involved for you?
You will receive the approved standard treatment for your cancer, a targeted therapy (palbociclib) in combination with an endocrine therapy (fulvestrant), and well as the inavolisib or placebo. Inavolisib is a tablet taken by mouth each day. Fulvestrant is a monthly injection and palbociclib is a tablet taken by mouth once a day for 21 days and then not taken for 7 days. It will involve seeing the doctor and coordinator for study visits every month for physical exams, ECG's, blood tests, tumour assessments (ie-CT scans).